Protein kinase C-β inhibition: A promise not yet fulfilled

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 4, 2007, Pages 619-620

  Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C; PROTEIN KINASE C BETA;

DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG ANTAGONISM; HUMAN; NOTE;

DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; PROTEIN KINASE C;

EID: 34548846951     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01940507     Document Type: Editorial

References (14)

1. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stratum LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272: 728-731, 1996
2. Koya D, King GL: Protein kinase C activation and the development of diabetic complications. Diabetes 47: 859-866, 1998
3. Frank RN: Potential new medical therapies for diabetic retinopathy: Protein kinase C inhibitors. Am J Ophthalmol 133: 693-698, 2002
4. Joy SV, Scates AC, Bearelly S, Dar M, Taulien CA, Goebel JA, Cooney MJ: Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother 39: 1693-1699, 2005
5. Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ, Garvey WT: Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: Associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications 19: 18-25, 2005
6. Fujisawa T, Ikegami H, Yamato E, Kawaguchi Y, Ueda H, Shintani M, Nojima K, Kawabata Y, Ono M, Nishino T, Noso S, Yamada K, Babaya N, Okamoto N, Ohguro N, Fukuda M, Ogihara T: Association of plasma fibrinogen level and blood pressure with diabetic retinopathy, and renal complications associated with proliferative diabetic retinopathy, in type 2 diabetes mellitus. Diabet Med 16: 522-526, 1999
7. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351: 28-31, 1998
8. Stephenson JM, Fuller JH, Viberti GC, Sjolie AK, Navalesi R: Blood pressure, retinopathy and urinary albumin excretion in IDDM: The EURODIAB IDDM Complications Study. Diabetologia 38: 599-603, 1995
9. Chugh A, Bakris GL: Microalbuminuria: What is it? Why is it important? What should be done about it? An update. J Clin Hypertens (Greenwich) 9: 196-200, 2007
10. Garg JP, Bakris GL: Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 7: 35-43, 2002
11. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49: S12-S154, 2007
12. Tuttle KR, McGill JB, Haney DJ, Lin TE, Anderson PW; for the PKC-DRS, PKC-DMES, and PKC-DRS 2 Study Groups: Kidney outcomes in long-term studies of roboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2: 631-636, 2007
13. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW: The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28: 2686-2690, 2005
14. McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, Hyslop DL: Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opin Drug Saf 5: 835-845, 2006